{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T22:01:27Z","timestamp":1764540087356,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.clml.2011.12.005","type":"journal-article","created":{"date-parts":[[2012,1,30]],"date-time":"2012-01-30T21:36:32Z","timestamp":1327959392000},"page":"132-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["The Importance of IGHV Mutational Status in del(11q) and del(17p) Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"12","author":[{"given":"Douglas E.","family":"Gladstone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Blackford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunpi","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lode","family":"Swinnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvette","family":"Kasamon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher D.","family":"Gocke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constance A.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Bola\u00f1os-Meade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.12.005_bib1","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.12.005_bib2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2009-03-210591","article-title":"De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience","volume":"114","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.005_bib3","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.3109\/10428194.2010.527403","article-title":"Chronic lymphocytic leukemia in a Japanese population: varied immunophenotypic profile, distinctive usage of frequently mutated IGH gene, and indolent clinical behavior","volume":"51","author":"Tomomatsu","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2011.12.005_bib4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/leu.2008.260","article-title":"A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease","volume":"23","author":"Best","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.12.005_bib5","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.3109\/10428194.2011.585529","article-title":"Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia","volume":"52","author":"Gladstone","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2011.12.005_bib6","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.005_bib7","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.005_bib8","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.V99.3.1023","article-title":"CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease","volume":"99","author":"Hamblin","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.005_bib9","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/cncr.23671","article-title":"Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia","volume":"113","author":"Kharfan-Dabaja","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.12.005_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/CBM-2009-0114","article-title":"ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia","volume":"6","author":"Trojani","year":"2010","journal-title":"Cancer Biomark"},{"key":"10.1016\/j.clml.2011.12.005_bib11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2011.12.005_bib12","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood-2010-03-275420","article-title":"Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial","volume":"116","author":"Dreger","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.005_bib13","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1200\/JCO.2008.16.2982","article-title":"Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis","volume":"26","author":"Schetelig","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011006124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011006124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:38Z","timestamp":1761870158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011006124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S2152265011006124"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.12.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Importance of IGHV Mutational Status in del(11q) and del(17p) Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}